Precipio (PRPO) Stock Overview
A healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
PRPO Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Precipio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$17.58 |
| 52 Week High | US$22.38 |
| 52 Week Low | US$3.90 |
| Beta | 1.09 |
| 1 Month Change | 23.85% |
| 3 Month Change | 56.36% |
| 1 Year Change | 170.38% |
| 3 Year Change | -1.28% |
| 5 Year Change | -64.13% |
| Change since IPO | -99.35% |
Recent News & Updates
Precipio, Inc.'s (NASDAQ:PRPO) Shares Leap 28% Yet They're Still Not Telling The Full Story
Sep 08
Precipio: Cash Flow Positivity May Remove Going Concern Language
Aug 07Further Upside For Precipio, Inc. (NASDAQ:PRPO) Shares Could Introduce Price Risks After 41% Bounce
Jul 12Recent updates
Precipio, Inc.'s (NASDAQ:PRPO) Shares Leap 28% Yet They're Still Not Telling The Full Story
Sep 08Precipio: Cash Flow Positivity May Remove Going Concern Language
Aug 07Further Upside For Precipio, Inc. (NASDAQ:PRPO) Shares Could Introduce Price Risks After 41% Bounce
Jul 12Investors Still Aren't Entirely Convinced By Precipio, Inc.'s (NASDAQ:PRPO) Revenues Despite 28% Price Jump
Feb 20Investors Aren't Entirely Convinced By Precipio, Inc.'s (NASDAQ:PRPO) Revenues
Dec 20Market Might Still Lack Some Conviction On Precipio, Inc. (NASDAQ:PRPO) Even After 29% Share Price Boost
Aug 21Here's Why Shareholders May Want To Be Cautious With Increasing Precipio, Inc.'s (NASDAQ:PRPO) CEO Pay Packet
Jun 07Investors Holding Back On Precipio, Inc. (NASDAQ:PRPO)
Mar 29Precipio, Inc.'s (NASDAQ:PRPO) Subdued P/S Might Signal An Opportunity
Aug 29Precipio to distribute HemeScreen through Fisher Healthcare channel
Jul 20We Think Some Shareholders May Hesitate To Increase Precipio, Inc.'s (NASDAQ:PRPO) CEO Compensation
Jun 12Shareholder Returns
| PRPO | US Healthcare | US Market | |
|---|---|---|---|
| 7D | 0.1% | 2.8% | 0.3% |
| 1Y | 170.4% | -21.6% | 17.4% |
Return vs Industry: PRPO exceeded the US Healthcare industry which returned -22.7% over the past year.
Return vs Market: PRPO exceeded the US Market which returned 17.6% over the past year.
Price Volatility
| PRPO volatility | |
|---|---|
| PRPO Average Weekly Movement | 10.1% |
| Healthcare Industry Average Movement | 6.6% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.1% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: PRPO has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: PRPO's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 57 | Ilan Danieli | www.precipiodx.com |
Precipio, Inc., a healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; and HemeScreen, a suite of robust genetic diagnostic panels.
Precipio, Inc. Fundamentals Summary
| PRPO fundamental statistics | |
|---|---|
| Market cap | US$29.12m |
| Earnings (TTM) | -US$1.80m |
| Revenue (TTM) | US$21.24m |
Is PRPO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PRPO income statement (TTM) | |
|---|---|
| Revenue | US$21.24m |
| Cost of Revenue | US$11.75m |
| Gross Profit | US$9.49m |
| Other Expenses | US$11.29m |
| Earnings | -US$1.80m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.11 |
| Gross Margin | 44.69% |
| Net Profit Margin | -8.48% |
| Debt/Equity Ratio | 0.7% |
How did PRPO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/09/24 16:27 |
| End of Day Share Price | 2025/09/24 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Precipio, Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Benjamin Haynor | Alliance Global Partners |
| Jason McCarthy | Maxim Group |